Deucravacitinib in PG
Novel Treatment of Pyoderma Gangrenosum With Deucravacitinib
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Phase
Phase
- Early Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Staci L Shaw
- Phone Number: (603) 650-3693
- Email: Staci.L.Shaw@hitchcock.org
Study Locations
-
-
New Hampshire
-
Lebanon, New Hampshire, United States, 03576
- Dartmouth-Hitchcock Medical Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Men and women between the ages of 18-70 years old
- Diagnosed with pyoderma gangrenosum requiring one major and at least 4 minor criteria
- Women must not be pregnant, lactating, or planning pregnancy during the study period
- Women of child-bearing potential must be on birth control for the duration of the treatment period.
- Subjects must agree to the use of at least one of the following contraception methods for the entire duration of the study until at least 30 days after taking their last dose of study drug:
- Women: Hormonal contraception (oral, injections, patch, implant, or vaginal-ring); Spiral (with or without hormones); any sterilization methods; a partner who has had a vasectomy; or sexual abstinence.
- Other acceptable methods of contraception are male or female condoms (with or without spermicide) or a cap, diaphragm, or sponge with spermicide.
- Willing to discontinue topical and/or systemic therapies, with the exception of oral rescue therapy with steroids.
- The wash period for systemic therapies will largely depend on the specific treatment but, in general, will be at least 6 months for biologics and 3 months for other immune- suppressants such as cyclosporine, mycophenolate mofetil, methotrexate, etc. No wash out period is required for topicals.
- Capable and willing to sign Institutional Review Board/IEC-approved written informed consent form in accordance with regulatory and institutional guidelines before the performance of any protocol-related procedures.
Exclusion Criteria:
- Patient under 18 years of age.
- Patients with a history of inflammatory bowel disease.
- Patients on systemic immunosuppressive/immune modulating therapy including: oral steroids, cyclosporine, mycophenolate mofetil, methotrexate, Azathioprine or TNFα inhibitor at time of starting deucravacitinib.
- Patients currently enrolled in another investigational study.
- Patients with a history or evidence of active infection and/or febrile illness within 7 days; or serious infection requiring antibiotic treatment within 30 days
- Hepatitis C virus (HCV): subjects known to be positive for anti-HCV antibody or for HCV RNA detectable by polymerase chain reaction (PCR)
- Hepatitis B virus (HBV): subjects known to be positive for hepatitis B surface antigen or for HBV DNA detectable by PCR
- Human Immunodeficiency Virus (HIV) infection: subjects known to be HIV positive
- History of active or inadequately treated latent tuberculosis (TB)
- Known or suspected systemic or skin autoimmune disorder other than pyoderma gangrenosum
- Any unstable major illness or evidence of unstable condition of major organ systems including psychiatric
- Cancer or history of lymphoproliferative disease within last 5 years; exception is cutaneous basal cell carcinoma or squamous cell carcinoma that has been treated.
- Major surgery within the last 4 weeks
- Live vaccines within the last 60 days
- Leukopenia (absolute WBC count < 3000/mm3); Lymphopenia (ALC < 500/mm3); Neutropenia (ANC < 1000/mm3)
- Thrombocytopenia (platelet count < 100,000/mm3; Anemia (hemoglobin < 9.0g/dL)
- ALT/AST > 3 X ULN and/or Total, unconjugated, and/or conjugated bilirubin > 2 X ULN within 28 days of dosing
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Deucravacitinib
Participants to receive Deucravacitinib 6 mg tablets orally twice daily for 12 weeks.
|
6 mg tablet
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Physician's Global Assessment (PGA)
Time Frame: Baseline; Days 8, 15, 29, 57, and 85; Follow up Day 115
|
PGA will be used for overall assessment of efficacy.
|
Baseline; Days 8, 15, 29, 57, and 85; Follow up Day 115
|
|
Change from baseline in ulcer size measured by calculating the area of the ulcers in centimeters squared using a digital application.
Time Frame: Baseline; Days 8, 15, 29, 57, and 85; Follow up Day 115
|
imitoAG application for mobile devices will be used to calculate the dimensions of the ulcers in centimeters to determine if the size of the ulcers is changed by the treatment.
|
Baseline; Days 8, 15, 29, 57, and 85; Follow up Day 115
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The percentage of patients needing rescue therapy from baseline to Day 115
Time Frame: Baseline through Day 115
|
Determining the number of participants that required rescue therapy while on study.
|
Baseline through Day 115
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Brian J. Simmons, MD, Dartmouth-Hitchcock Medical Center
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- STUDY02001753
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.